2019 INNOVATION OFFICE of - Moffitt Cancer Center
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
OFFICE of INNOVATION and Industry Alliances 2019 ANNUAL REPORT
Contents
3 Executive Message
4 CARs of the Future with Atara
5 Dr. List Recognized at Florida Inventors Hall of Fame
6 Manufacturing a Cure with Iovance
7 Moffitt and Precigen Team Up
to Change Prognosis
8 Avoiding Attacks on Healthy Cells
with TuHURA
9 FY 2019 Innovation Index
10 Matchmakers: Industry Alliances
Builds Relationships
12 13th Annual Business
of Biotech Conference
14 U.S. Patents Issued FY 2019
Executive Message
FISCAL YEAR 2019 has been another banner year for the Innovation
Office. Through our licensing and partnering successes, we
generated $36M in funding this year, which brings our five-year
funding to $147M. This year’s successes are due to people within
the Innovation Office and many beyond our doors. This annual
report highlights several high profile Moffitt partnerships. Among
our accomplishments this year, we collaborated with Iovance
Biotherapeutics to manufacture cells on their behalf, we are working
with Atara Biotherapeutics to discover more targeted therapies
and we are assisting a startup, TuHURA Biopharma, to improve the L. David de la Parte, Esq.
effectiveness of immunotherapy in cancer patients and to spare Executive Vice President/
General Counsel
patients’ healthy cells. We are offering new hope to patients with Office of General Counsel
relapsed or refractory acute myeloid leukemia through a clinical trial
with Precigen’s therapeutic platform.
The Innovation Office has undergone a series of organizational
changes to enhance its partnership efforts. During the year, we
established a new business unit, Innovation Services, to support
patenting, licensing and industry partnering. Staff members
that negotiate material transfer and confidentiality agreements
transitioned to the Office of General Counsel.
James J. Mulé, PhD
During fiscal year 2019, 24 Moffitt U.S. patents were issued. This is Associate Center Director,
Translational Science
a testament of the amazing science and innovation by Moffitt team
members. Dr. Alan List, President and CEO, is a prolific inventor with
six issued patents and 49 U.S. and international patent applications.
Ten of his technologies are currently licensed to industry partners
for ongoing development of cancer treatments. Because of Dr. List’s
breakthrough discoveries during his career, he was inducted into the
2019 Florida Inventors Hall of Fame. Congratulations to Dr. List and all
of the Moffitt inventors on their discoveries.
The successes of the Innovation Office would not have been possible
Jarett Rieger, Esq., MBA
without the insights and input from the Moffitt Patent Review Senior Director,
Committee and Moffitt Commercialization Strategy Committee. Innovation & Industry Alliances
The office looks forward to working with these committees and the
Moffitt team members to advance technologies through partnerships
and commercialization.
3
O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S F Y 2 0 1 9
CARs OF THE FUTURE
with Atara
ATARA BIOTHERAPEUTICS is a leading T-cell immunotherapy company that develops novel
treatments for patients with cancer, as well as patients with viral and autoimmune diseases.
Moffitt and Atara forged a strategic partnership encompassing several scientific endeavors:
development of a genetically engineered cell therapy for patients with acute myeloid leukemia
(AML); multi-antigen targeted CAR T-cell therapy; first-generation signaling technology for
CARs; and next-generation signaling technology for CARs. The goal of this collaboration is to
develop CAR T cells that are more efficient, more likely to respond, and capable of working
against more diverse B cell or AML hematological malignancies.
We hope to develop a better targeted therapy that will stay engaged, produce better response
and last longer, while simultaneously sparing the healthy cells.
“The biggest advantage is our shared commitment to bring this technology and therapeutic
advancement to patients as quickly as possible,” stated Marco Davila, MD, PhD, Associate
Member of Moffitt’s Immunology Program.
“Together with Moffitt, we are committed to discovering innovative
medicines and enabling efficient product development. Moffitt’s
ability to bring cutting-edge research, patients who need innovation
and manufacturing all together in one center is unique, especially
for CAR T therapy,” stated Dan Maziasz, Vice President and Head of
Business Development and Alliance Management
at Atara Biotherapeutics.
These research projects are expected to lead to
new clinical trials and to improve the overall care
of patients.
“The biggest advantage is our shared
commitment to bring this technology and
therapeutic advancement to patients as
quickly as possible.”
4
F Y 2 0 1 9 O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S
Dr. List
Recognized
AT FLORIDA INVENTORS
HALL OF FAME
Congratulations to ALAN LIST, MD, PRESIDENT
AND CEO of Moffitt Cancer Center, for his
induction into the 2019 Florida Inventors Hall of
Fame. The Florida Inventors Hall of Fame is an
initiative that recognizes and honors scientists who are dedicated to patient quality of care
throughout Florida and nationwide. All nominations undergo a competitive review and selection
process in which only six to eight nominees are inducted each year. Nominees must be a named
inventor on a patent issued by the United States Patent and Trademark Office, have an invention
that was commercialized, utilized or led to an important innovation and have a significant impact
to society as a whole.
Dr. List is being recognized for his dedication to finding treatments for cancer. He has contributed
to the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). As a
result of these efforts, lenalidomide (Revlimid®) was developed and approved by the FDA for
use on patients with MDS and multiple myeloma. Revlimid® transformed the history of MDS to a
condition that can be managed and treated in the outpatient setting with an oral agent.
PATENTS ISSUED FOR DR. LIST:
• Methods of Using Aminothiols to Promote Hematopoietic Progenitor Cell Growth
• Method of Identifying Myelodysplastic Syndromes
• RNF41 as a Biomarker Predicting Response to Lenalidomide in Non-del(5q) MDS
• Targeted Sensitization of Non-del(5q) Malignant Cells
• Protein Phosphatase 2A Inhibitors for Treating Myelodysplastic Syndromes
• Soluble CD33 for Treating Myelodysplastic Syndromes (MDS)
5
O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S F Y 2 0 1 9
MANUFACTURING A CURE
with Iovance
DURING THE PAST YEAR, Moffitt Cancer Center has expanded its relationship
with Iovance Biotherapeutics, a clinical stage biotechnology company.
Iovance is primarily focused on developing and commercializing novel cancer
immunotherapies based on tumor infiltrating lymphocytes (TIL).
The Iovance and Moffitt partnership began in 2014 and has resulted in the successful
development of TIL therapies for cancer. During the first project, Iovance worked
closely with Moffitt and became familiar with the cancer center’s resources, most
notably Moffitt’s Cell Therapies Shared Resource.
Moffitt’s Cell Therapies Shared Resource manufactures safe therapeutic cellular
products in support of clinical studies. The Cell Therapies Shared Resource takes part
in new product development, cell collection, cell therapy product manufacturing and
product quality testing. These unique capabilities caught the attention of Iovance and
led to Moffitt’s first manufacturing agreement. The expansion with Iovance is expected
to result in more clinical trials for a variety of new indications.
The partnership between
Iovance and Moffitt began in
2014 and has resulted in the
successful development of TIL
therapies for cancer.
6
F Y 2 0 1 9 O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S
Moffitt and Precigen
TEAM UP TO CHANGE PROGNOSIS
MOFFITT CANCER CENTER AND PRECIGEN INC., a biopharmaceutical company specializing
in the development of innovative gene and cellular therapies, announced the first patient dosed
in their clinical trial using Precigen’s non-viral PRGN-3006 UltraCAR-T™ therapeutic platform.
These therapies are targeted toward patients with relapsed or refractory acute myeloid leukemia
(AML) or higher-risk myelodysplastic syndromes (MDS). This collaborative study is expected to
improve precision and control in targeting relapsed or refractory AML and higher-risk MDS as
well as reduce manufacturing related costs and increase process efficiencies.
The American Cancer Society estimates 21,450 new cases of AML will be diagnosed in the
United States during 2019. AML is a rare cancer that begins in the bone marrow and often
spreads to the blood. Patients with AML have an average survival rate of approximately five
years. MDS are cancerous conditions of the bone marrow that can progress to AML.
“AML is an aggressive disease with very poor prognosis,” said James J. Mulé, PhD, Associate
Center Director and Michael McGillicuddy Endowed Chair in Melanoma Research and Treatment,
at Moffitt Cancer Center. "The first patient dosed with investigational PRGN-3006 UltraCAR-T™
represents a significant development for this challenging patient population with high unmet
medical need.”
“AML and MDS patients have few treatment options,
and time is critical when selecting the best treatment
path," said David A. Sallman, MD, lead investigator The collaboration between Moffitt
for the PRGN-3006 study. “We are hopeful that this Cancer Center and Precigen is expected
study will be the beginning of the development of
to yield key advancements in the
treatment of AML and MDS patients.
a therapy that may result in a critically needed new,
safe and efficacious treatment option that allows for
rapid treatment.”
We are hopeful that this collaboration between Moffitt and Precigen will yield key
advancements in the treatment of AML and MDS.
7
O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S F Y 2 0 1 9
Avoiding Attacks
On Healthy Cells
WITH TuHURA
TUHURA BIOPHARMA, a startup biotechnology company, and
Moffitt Cancer Center have partnered to develop a new generation of
targeted immunotherapies that can be applied to a greater number of
cancers and a larger patient population. Moffitt will have the opportunity to
develop its first-in-class bifunctional immunoconjugates, which are cancer
cell binding agents that help target the tumor’s microenvironment while
avoiding non-cancerous cells. These novel bifunctional immunoconjugates
are designed to improve the effectiveness of immunotherapy and may
potentially spare healthy cells to reduce a patient’s chance of developing
severe side effects.
TuHURA was impressed with Moffitt’s research. “Having reviewed more
than 100 new technologies among 40 leading academic institutions and
cancer research centers across the United States, we found the technology
developed at Moffitt has the greatest potential to advance the field of
cancer immunotherapy. Decreasing the immune suppression caused
by the tumor microenvironment is an area of intense research among
both academic and pharmaceutical research,” said James A. Bianco,
MD, TuHURA's Principal Founder and Executive Chairman.
Moffitt is equally eager to be working on this project with TuHURA.
“With this agreement, Moffitt can build on the incredible
advancements we have seen in immuno-oncology, bringing
novel treatments to patients, while delivering a safer and
more effective approach,” said Alan List, MD, Moffitt
President and CEO.
8
F Y 2 0 1 9 O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S
FY 2019
Innovation Index
56 original U.S. patent
applications
licenses
12
global $ 36 funding
11
MILLION
active startups
intellectual property
disclosures
59
213
worldwide patent
applications
24 U.S. patents issued
9
O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S F Y 2 0 1 9
Matchmakers:
INDUSTRY ALLIANCES
BUILDS RELATIONSHIPS
THE INNOVATION OFFICE’S INDUSTRY ALLIANCES BUSINESS UNIT launched five years ago.
The unit started with one person, Dr. Latanya Scott, and has steadily grown to a four-person
workgroup. In this short time, Industry Alliances has generated over $100M in global revenue for
Moffitt. This is a remarkable feat for a newly created team.
Finalizing deals is not easy and it certainly is not
Industry Alliances’ focus is to make fast. We know what companies want, but Industry
sure that the faculty needs and Alliances’ focus is to make sure that the faculty’s
Moffitt's goals are front and center needs and Moffitt’s goals are front and center
throughout any process. throughout the process. We ask faculty, “Would
additional funding be beneficial to support your
lab personnel? Is access to data from Moffitt
biospecimens too costly for you to generate on your own? Can we help you gain access to
novel technologies that will help springboard your research interests and support new grant
applications and publications”?
Our office acts as the matchmaker to align scientific interests between faculty and industry.
After a match is identified, the hard steps begin. It is similar to a dance with many twists, turns
and spins to determine statements of work and budgets. This initial stage of the relationship
involves faculty and maintaining a focus to keep a prospective company’s interest alive and well.
Industry Alliances shepherds the process along and negotiates the terms for Moffitt. This is a
challenging process with only about half of the potential relationships surviving this phase. As a
project comes together, usually following a lengthy negotiation period, the matchmaking is almost
complete and the final approval steps begin.
There is no “usual” to matchmaking. Each faculty member, each company and each project is
unique. The Industry Alliances staff works diligently to develop relationships that will be beneficial
to Moffitt and its faculty.
10
F Y 2 0 1 9 O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E SMEET THE MATCHMAKERS
L ATA N YA S C OT T
Associate Director
Industry Alliances
INDUSTRY
COLLABORATION BENEFITS
• Funding Faculty Research
• Collaborate with Industry
Scientists
• Translational & Clinical
Applications of Faculty Studies
• Data for High Quality Publications
• Access to Novel Drugs/Proprietary
Pipelines
A LE X I S K A R A N D R E A RUA N C OX
• Access to Cutting Edge Research
Industry Alliance Technologies Industry Alliance
Development Manager Development Manager
• Generation of Novel Intellectual
Property
V E RO N I K A F E D O RC H U K
Industry Alliance
Development Specialist
11
O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S F Y 2 0 1 913TH ANNUAL
BUSINESS OF BIOTECH
CONFERENCE
Cracking the Cancer Code
THE 13TH ANNUAL BUSINESS OF BIOTECH conference held Feb.22, 2019,
set a new attendance record of 458 diverse individuals from biotech companies,
universities, startups, investors and international entrepreneurs.
The keynote address was conducted as a fireside chat between Dr. Reid Huber (Partner at Third
Rock Ventures and former Chief Scientific Officer at Incyte) interviewed by Cokie Roberts*
(ABC News Political Commentator, NPR Contributing Senior News Analyst and member of
Moffitt’s National Board of Advisors). During the interview, Dr. Huber described the process
of creating a new company with two major components: the initial therapeutic drug discovery
program and the future product engine.
The four educational sessions were well attended and received excellent reviews. Guests
enjoyed time discussing collaboration and partnering opportunities. On the day prior to the
conference a record breaking Partnering Forum was held, which included 60 individual industry
partnering meetings.
12
F Y 2 0 1 9 O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E SFOUR EDUCATION SESSIONS:
• Navigating FDA Approvals for Cell Therapy
• Clinical Pathways: Tackling Value-Based Cancer Care
• Artificial Intelligence in Cancer Care Delivery:
The Robot Will See You Now
• E-I-E-I-O! Sowing, Growing and Reaping Immune
Oncology Production
SAVE THE DATE:
ACCOMPLISHMENTS:
• ATTENDEES: 458
February 7, 2020
44 Biotech Companies, 14 Economic Development 14th Business of Biotech
Groups/Investors, 9 Colleges/Universities and 7 Science Institutions Conference
Visit MoffittIP.com to register.
• MEDIA COVERAGE: Moffitt press release distributed to
69 journalists Partnering Forum
• SOCIAL MEDIA COVERAGE: 46 posts using the “MoffittBOB” February 6, 2020
hashtag BY INVITATION ONLY
• SPONSORSHIPS: $57,500 raised; 21 sponsors To find out more, email
INNOVATION@Moffitt.org
• PARTNERING FORUM/NETWORKING EVENTS: 75 interactions
* As this annual report went to press, we learned that our dear colleague
Cokie Roberts passed away. She will be greatly missed.
13
O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S F Y 2 0 1 924 U.S. Patents Issued FY 2019
PATENT INVENTORS
Anesthesia Gas Delivery and Monitoring System Chaudhry, Tariq
Biomarkers and Methods for Predicting Benefit of Cress, Douglas
Adjuvant Chemotherapy Chen, Dung-Tsa
CD28 Expression During Lenalidomide Immune Modulation Burnette, Pearlie
McDaniel, Jessica
Cyclic Peptide Conjugates and Methods of Use Hazlehurst, Lori
McLaughlin, Mark
Rader, Christoph
Li, Xiuling
Histone Deacetylase 6 Inhibition for Enhancing T-Cell Function Sotomayor, Eduardo
During Anti-Tumor Response and Tumor-Peptide Vaccination Villagra, Alejandro
Immune Gene Signatures in Cancer Mulé, James
Yeatman, Timothy
Coppola, Domenico
Loboda, Andrey
Nebozhyn, Michael
Inhibitors of ACK1/TNK2 Tyrosine Kinase Mahajan, Nupam
Lawrence, Nicholas
Lawrence, Harshani
Mahajan, Kiran
Integrin Interaction Inhibitors for the Treatment of Cancer Dalton, William
Hazlehurst, Lori
McLaughlin, Mark
Jain, Priyesh
Method of Assessing Breast Density for Breast Cancer Sellers, Thomas
Risk Applications Heine, John
Fowler, Erin E
Method of Ex Vivo Enhancement Of Immune Cell Activity for Cancer Pilon-Thomas, Shari
Immunotherapy With A Small Molecule Ablative Compound Sarnaik, Amod
Singer, Jamie
Liu, Hao
Wachter, Eric
Method of Increasing Intratumoral pHe and Reducing Gillies, Robert
Acid-Mediated Invasion Morse, David
Gatenby, Robert
Silva, Ariosto
Martinez, Gary
Ibrahim Hashim, Arig
Methods and Systems for Performing Segmentation and Guo, Yanhui
Registration of Images Using Neutrosophic Similarity Scores Gonzalez, Segundo Jaime
14
F Y 2 0 1 9 O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E SPATENT INVENTORS
Methods and Systems for Predicting Cancer Outcome Eschrich, Steven
Bloom, Gregory
Yeatman, Timothy
MicroRNA Assay for Detection and Management of Malafa, Mokenge
Pancreatic Cancer Precursors Chen, Dung-Tsa
Permuth Wey, Jennifer
Pathology Case Review, Analysis and Prediction Bui, Marilyn Yuanxin Ma
Lloyd, Mark
Rejniak, Katarzyna
Puri, Munish
Personalized Myeloma Detection Koomen, John
PET Probes of Radiofluorinated Carboximidamides for Gillies, Robert
IDO-Targeted Imaging Tian, Haibin
Potent Dual BRD4-Kinase Inhibitors as Cancer Therapeutics Lawrence, Nicholas
Lawrence, Harshani
Schonbrunn, Ernst
Protein Phosphatase 2A Inhibitors for Treating List, Alan
Myelodysplastic Syndromes Sallman, David
Kovach, John
Protein-Protein Interaction as Biomarkers Haura, Eric
Selective Histone Deactylase 6 Inhibitors Sotomayor, Eduardo
Bergman, Joel
Kozikowski, Alan
Villagra, Alejandro
Woan, Karrune (Winston)
Small Molecule Inhibitors of STAT3 with Anti-Tumor Activity Sebti, Saïd
Turkson, James
Lawrence, Nicholas
Lawrence, Harshani
Guida, Wayne
Yip, Man Lun (Richard)
Greedy, Benjamin
Stabilized Peptoid-Peptide Hybrids and Uses Thereof Sarnaik, Amod
McLaughlin, Mark
Toll-Like Receptor 2 (TLR2) Ligands and Methods of Making McLaughlin, Mark
and Using Thereof Gillies, Robert
Morse, David
Huynh, Amanda
Doligalski, Michael
Vagner, Josef
15
O F F I C E O F I N N O VAT I O N A N D I N D U S T R Y A L L I A N C E S F Y 2 0 1 9OFFICE of INNOVATION and Industry Alliances For business development opportunities please contact: Haskell Adler, PhD, MBA Senior Licensing Manager Haskell.Adler@Moffitt.org 813.745.6596 Ruan Cox, PhD Industry Alliance Development Manager Ruan.Cox@Moffitt.org 813.745.6851 Veronika Fedorchuk, PhD Industry Alliance Development Specialist Veronika.Fedorchuk@Moffitt.org 813.745.2887 Alexis Karandrea, PhD Industry Alliance Development Manager Alexis.Karandrea@Moffitt.org 813.745.2257 Jarett Rieger, Esq., MBA Senior Director, Innovation & Industry Alliances Jarett.Rieger@Moffitt.org 813.745.6828 Latanya Scott, PhD Associate Director, Industry Alliances Latanya.Scott@Moffitt.org 813.745.6902 MoffittIP.com
You can also read
